Trial reportDrug and alcohol dependence2020
Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial.
Trial report in Drug and alcohol dependence, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Cost per Opioid-Free Year: A Systematic Review and Summary Analysis.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2025Pooled it
- Opioid agonist treatment for people who are dependent on pharmaceutical opioids.The Cochrane database of systematic reviews · 2022Pooled it
- Sensitivity to change of generic preference-based instruments (EQ-5D-3L, EQ-5D-5L, and HUI3) in the context of treatment for people with prescription-type opioid use disorder in Canada.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023Trial
- Determinants of health-related quality of life among individuals with opioid use disorder, recently released from incarceration.Addiction science & clinical practice · 2023Trial
- Methadone treatment and associated health and social outcomes after a national manufacturing closure in Mexico: a longitudinal observational cohort study in Tijuana.Lancet regional health. Americas · 2026Article
- Impacts of personal or family COVID-19 infection on health-related quality of life among patients with opioid use disorder.Journal of substance use · 2026Article
- Joint Trajectories of Insomnia Severity and Quality of Life Among Adults in Opioid Use Disorder Treatment: A Longitudinal Study With Parallel Process Latent Growth Curve Modelling.Journal of sleep research · 2026Article
- A Peer-Led, Narrative-Based, and Mobile-Supported Intervention in Opioid Use Disorder: Multiphase Qualitative and Longitudinal Observational Study.JMIR formative research · 2026Observational
- Health-related quality of life measures as predictors for recurrent hospitalization and mortality among patients in heroin-assisted treatment.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Review
- Evaluating Quality of Life Changes over 12 Months Among Opiate Users from Romania and Associated Worsening Factors.Life (Basel, Switzerland) · 2024Article
- Are the self-stigma and perceived stigma of patients treated with methadone or buprenorphine still a problem fifty years after the marketing authorization for opioid agonist treatment? The observational STIGMA study.Addiction science & clinical practice · 2024Observational
- Informing evidence-based medicine for opioid use disorder using pharmacoeconomic studies.Expert review of pharmacoeconomics & outcomes research · 2024Review
- Emergency-department initiated buprenorphine: Impact on quality of life.Drug and alcohol dependence reports · 2023Article
- Health-related quality of life and recovery capital among recovery residents taking medication for opioid use disorder in Texas.Frontiers in public health · 2023Article
- Econometric Issues in Prospective Economic Evaluations Alongside Clinical Trials: Combining the Nonparametric Bootstrap With Methods That Address Missing Data.Epidemiologic reviews · 2022Review
- Patient-centered quality measurement for opioid use disorder: Development of a taxonomy to address gaps in research and practice.Substance abuse · 2022Review
- Sociodemographic and Clinical Characteristics Associated with Improvements in Quality of Life for Participants with Opioid Use Disorder.Healthcare (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveTo examine the health-related quality-of-life (HRQoL) of persons with opioid use disorder (OUD) seeking treatment in an inpatient detoxification or short-term residential setting; continuing treatment as outpatients.
methodsWe conducted a secondary analysis of data from a clinical trial (N = 508) where participants were randomized to extended-release naltrexone or buprenorphine-naloxone for the prevention of opioid relapse. We used a generalized structural equation regression mixture model to identify associations of HRQoL (EQ-5D) trajectories, including latent characteristics, over the 24-week trial and 36-week follow-up period, among participants who reported HRQoL beyond baseline. This novel framework accounted for baseline and time-varying characteristics, while simultaneously identifying latent classes.
resultsWe identified two subpopulations: HRQoL "pharmacotherapy responsive" (82.3 %) and HRQoL "characteristic sensitive" (17.7 %). The pharmacotherapy responsive subpopulation was characterized by a shortterm HRQoL improvement and then stable HRQoL over time, and by a positive association between HRQoL and receiving pharmacotherapy in the past 30 days. The characteristic sensitive subpopulation was characterized by an initial improvement in HRQoL with a gradual decline over time, and no significant HRQoL response to pharmacotherapy. HRQoL changes over time in this subpopulation were more influenced by baseline demographic, socioeconomic, and psychosocial characteristics.
conclusionOur findings suggest that while HRQoL may be improved and sustained through targeted efforts to promote use of pharmacotherapy for many persons with OUD, an identifiable subpopulation may require additional services that address socioeconomic and psychosocial issues to achieve HRQoL benefits. Our analysis provides insight for improving individualized care for persons with opioid use disorder seeking treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.